BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income turns positive

Q3 FY2026 net income was $27.31B, compared with -$30.74M a year earlier. Trailing-twelve-month net income was $27.6B. Over 3 fiscal years it compounded at +35.1% a year.

Context

  • Net income amounted to 10.8% of revenue in FY2025, down 4.1 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 20 analysts of $592.26M (+69.8%) for the fiscal year ending Dec 2026, a step up from the -18.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$27.31B+60906.5% QoQ
Last fiscal yearDec 2025
$348.9M-18.3% YoY
LTMSep 2026
$27.6B+3808.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+88922.9%+14.7%-88908.2 pp
1 year-18.3%+69.8%+88.0 pp
3-year CAGR+35.1%+61.8%+26.7 pp
5-year CAGR+39.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
348.9M USD
Year-over-year change
-18.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3808.4% is the highest of 11, against a peer median of +43.1%.
  • Net income amounts to 2.7% of revenue for BMRN, versus a peer median of 45.9%.
BMRN Competitors
Net Income for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$27.6B USD+3808.4%+35.1%2.7%
VRTXVertex Pharmaceuticals IncorporatedLTM Jun 2026$4.41B USD+21.1%+6.0%34.9%
ASNDAscendis Pharma A/SLTM Sep 2026€890.37M EUR+482.2%-27.9%73.7%
INSMInsmed IncorporatedLTM Jun 2026$875.31M USD-15.4%+38.4%76.9%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$807.99M USD+353.2%—16.8%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$695.45M USD-11.4%+14.4%97.5%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$608.92M USD+10.8%-6.7%91.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$546.15M USD+113.1%+12.2%56.9%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$146.22M USD+65.1%-57.4%22.5%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$38.38M USD-106.1%—3.8%
PHARPharming Group N.V.LTM Mar 2026$14.61M USD+298.9%-42.4%4.0%
Peer median (excluding BMRN) —+43.1%-0.4%45.9%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.08M)141.56M167.65M426.86M348.9M
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
Deferred Income Tax(15.61M)(52.09M)(44.98M)56.1M48.74M
Stock-Based Compensation197.26M196.31M207.1M201.57M181.41M
Change in Working Capital66.03M(96.38M)(336.54M)(216.4M)(108.68M)
Accounts Receivables65.57M(82.03M)(190.44M)(57.91M)(228.05M)
Inventory(35.06M)(68.26M)(157.06M)(63.53M)119.21M
Accounts Payables15.69M59.02M68.85M(32.24M)66.14M
Other Working Capital19.83M(5.1M)(57.9M)(62.72M)(65.97M)
Other Non-Cash Items12.89M(115.47M)61.65M8.29M278.07M
Operating Cash Flow304.54M175.9M159.26M572.84M827.99M
Capital Expenditures(119.23M)(120.96M)(107.61M)(97.42M)(103.04M)
Acquisitions (Net)0000(285.19M)
Purchases of Investments(937.14M)(611.81M)(868.5M)(410.25M)(355.88M)
Sales of Investments691.05M620M864.86M633.02M337.8M
Other Investing Activities(24.64M)103.33M(10.92M)(853K)(7.94M)
Investing Cash Flow(366.31M)(20.03M)(111.24M)136.49M(414.24M)
Debt Repayment(3.04M)(2.61M)(2.29M)(494.99M)0
Common Stock Issued069.33M69.35M014.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.99M(85.38M)(85.79M)(31.46M)(56.85M)
Financing Cash Flow(48K)(18.65M)(18.73M)(526.45M)(42.39M)
Effect of Forex Changes(57K)32K1.31M4.83M(2.52M)
Net Change in Cash(61.88M)137.26M30.6M187.72M368.84M
Free Cash Flow185.31M54.94M51.65M475.42M724.96M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.